October 07, 2005
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
B&L announces Medicare reimbursement for Retisert
ROCHESTER, N.Y. — An intravitreal implant for the treatment of chronic noninfectious uveitis affecting the posterior segment will have a Medicare payment rate of almost $20,000 when used in a hospital outpatient setting, according to a press release from Bausch & Lomb.
B&L said the Retisert payment methodology is based upon 106% of wholesale acquisition cost. The Centers for Medicare & Medicaid Services has designated the single-indication orphan drug as eligible for Medicare pass-through payment under the Hospital Outpatient Prospective Payment System effective Oct. 1.
Retisert (fluocinolone acetonide intravitreal implant) 0.59 mg was launched in the United States in June, following approval by the Food and Drug Administration in April.